VEGFA and hepatocellular carcinoma: BIRC5-specific siRNA inhibited HCC cell growth and reversed drug resistance by inhibiting lung resistance-related protein (LRP) so that improved chemotherapy sensitivity in vitro and in vivo41.VEGFA is the most powerful Vascular endothelial growth factor (VEGF) subtype and the mechanisms involved in VEGF regulating in HCC included the HIF1-α pathway, HBx protein activation, tumor suppressor gene loss or inactivation, and multiple signal transduction pathways42.